Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wireless glucose sensors could transform ICU care — but can they deliver?

NCT ID NCT07769138

Knowledge-focused Sponsor: Imperial College Healthcare NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This study tests whether continuous glucose monitors (CGMs) like the Dexcom G7 can be safely and effectively used in intensive care units. The monitors provide real-time blood sugar readings and alarms for dangerously high or low levels, potentially reducing the need for frequent finger-prick tests. Researchers will track how many eligible patients agree to participate, how quickly monitoring starts, and how often the devices fail or cause issues. The goal is to see if this technology is practical for routine ICU use, not to measure its impact on patient outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dexcom G7 continuous glucose monitor with ViewsEMR telemetry
What this could lead to
If successful, this could make continuous glucose monitoring a standard, safe tool in intensive care, potentially reducing dangerous blood sugar swings in critically ill patients.
What could go wrong
This is a small, early observational study focused on feasibility, not outcomes. It may not prove clinical benefit, and device issues or skin reactions could limit use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults admitted to the intensive care unit with hyperglycaemia

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18years inclusive * Hyperglycaemia requiring insulin therapy (subcutaneous injection or intravenous insulin) during admission on ICU * Admission to ICU within 48hours Exclusion Criteria: * Known significant allergy to tape/ adhesives * Imminent death or anticipated length of stay \<24hours * Women who are pregnant * Imminent extracorporeal membrane oxygenation (ECMO) * Requirement for therapeutic temperature control (i.e. cooling) post cardiac arrest

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Continuous glucose monitoring are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus hyperglycemia hypoglycemia type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Continuous glucose monitoring Hyperglycemia Hypoglycaemia Intensive care (ICU) Type 1 diabetes Type 2 diabetes treated with insulin

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Imperial College Healthcare NHS Trust

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.